drugset
drugset / Trial / NCT01256398

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT01256398 ↗

Phase 2 Completed 66 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, may interfere with the ability of cancer cells to grow and spread. Giving more than one drug (combination chemotherapy) and giving dasatinib together with chemotherapy may kill more cancer cells.

Timeline

Start
2010-12-14
Primary completion
2017-11-14
Completion
2021-11-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject dasatinib anhydrous Small molecule — Oral
Background Alemtuzumab Monoclonal antibody — Intravenous
Background Cyclophosphamide Other / unclassified — Intravenous
Background Cytarabine Small molecule — Intravenous
Background Daunorubicin Small molecule — Intravenous
Background Dexamethasone Small molecule — Oral
Background Etoposide Small molecule — Intravenous
Background Fludarabine Small molecule — Intravenous
Background Leucovorin Small molecule — Intravenous
Background MERCAPTOPURINE ANHYDROUS Small molecule — Oral
Background Melphalan Small molecule — Intravenous
Background Methotrexate Small molecule — Intrathecal
Background Pegfilgrastim Protein / enzyme biologic — Subcutaneous
Background Tacrolimus Small molecule — Intravenous
Background Vincristine Small molecule — Intravenous
Background filgrastim Protein / enzyme biologic — Subcutaneous

Indications

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) acute lymphoblastic leukemia